Hypothesis

Berberine reduces circulating PCSK9 levels and enhances LDL clearance by reshaping the gut microbiome to increase secondary bile acid production, which activates intestinal FXR, elevates FGF19/15 signaling, and suppresses hepatic PCSK9 transcription through an ERK1/2‑dependent pathway that does not require AMPK activation.

Mechanistic Rationale

Berberine’s lipid‑lowering superiority over metformin suggests mechanisms beyond AMPK‑mediated metabolic effects [2]. While both drugs inhibit mitochondrial complex I to trigger AMPK, berberine’s lysosomal AMPK activation depends on AXIN1 but not PEN2 [1], and it can stimulate glucose uptake even when AMPKα is silenced [3]. This indicates parallel, AMPK‑independent routes. Recent work links metformin’s glucose‑lowering action to gut microbiome alterations and bile acid signaling; however, berberine’s impact on the microbiome and PCSK9 remains unexplored. We propose that berberine remodels luminal bacteria toward bile‑acid‑hydrolyzing taxa, raising levels of secondary bile acids such as deoxycholic acid (DCA) and lithocholic acid (LCA). These ligands activate the nuclear receptor FXR in enterocytes, driving FGF19 (human) or FGF15 (mouse) secretion. FGF19 binds hepatic FGFR4/β‑Klotho, triggering ERK1/2 phosphorylation, which suppresses SREBP‑2 activity and directly downregulates PCSK9 transcription, thereby increasing LDL receptor density and LDL catabolism. Because this cascade originates in the intestine and signals to the liver via FGF19, it can function even when hepatic AMPK is absent or inhibited.

Experimental Approach

1. Microbiome modulation: Treat high‑fat‑diet fed mice with berberine (200 mg/kg/day) or vehicle for 4 weeks. Collect feces for 16S rRNA sequencing to identify shifts toward bile‑acid‑metabolizing bacteria (e.g., Clostridium scindens). Parallel groups receive broad‑spectrum antibiotics to eradicate gut flora.
2. Bile acid quantification: Measure fecal and portal secondary bile acids (DCA, LCA) via LC‑MS.
3. FXR/FGF19 axis: Assess intestinal FXR target gene expression (Shp, Fgf15) and serum FGF19 levels. Use intestinal‑specific FXR knockout mice to test necessity.
4. Hepatic PCSK9 and LDLR: Quantify hepatic PCSK9 mRNA/protein, LDL‑R protein, and LDL uptake ex vivo. Include hepatocytes from AMPKα1/α2 double‑knockout mice to confirm AMPK independence.
5. Pharmacological inhibition: Administer the FXR antagonist glyco‑cholic acid or the FGFR4 inhibitor BLU‑9937 to determine if PCSK9 suppression is blocked.
6. Outcome measures: Plasma LDL‑C, triglycerides, and PCSK9 concentrations; hepatic ERK1/2 phosphorylation; aortic atherosclerosis en face analysis.

Expected Outcomes and Falsifiability

If the hypothesis is correct, berberine will: (a) enrich secondary bile‑acid‑producing bacteria, (b) raise portal DCA/LCA, (c) increase intestinal FXR activity and circulating FGF19, (d) reduce hepatic PCSK9 and elevate LDL‑R, and (e) lower LDL‑C. These effects will be absent in antibiotic‑treated, germ‑free, or intestinal FXR‑deficient mice, and will not be altered by hepatic AMPK knockout. Conversely, if berberine lowers PCSK9 independently of the microbiome‑FXR‑FGF19 axis (e.g., via direct hepatic AMPK or other pathways), then manipulating gut flora or FXR will not affect PCSK9 or LDL‑C despite berberine administration. This clear set of predictions renders the hypothesis testable and falsifiable.